

Instance: composition-en-c94b2bb5a2491f8b60f6777b6703f8a1
InstanceOf: CompositionUvEpi
Title: "Composition for livogiva Package Leaflet"
Description:  "Composition for livogiva Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "identifier"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mpdfc0d1e53a0834f3389ed5dd9c5233d8)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - livogiva"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #en
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What is in this leaflet</p>
<ol>
<li>What Livogiva is and what it is used for  </li>
<li>What you need to know before you use Livogiva </li>
<li>How to use Livogiva </li>
<li>Possible side effects  </li>
<li>How to store Livogiva </li>
<li>Contents of the pack and other information </li>
</ol>         </div>"""   
          

* section[=].section[+]
  * title =  "1. What livogiva is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What livogiva is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Livogiva contains the active substance teriparatide that is used to make the bones stronger, and to 
reduce the risk of fractures by stimulating bone formation.  </p>
<p>Livogiva is used to treat osteoporosis in adults. Osteoporosis is a disease that causes your bones to 
become thin and fragile. This disease is especially common in women after the menopause, but it can 
also occur in men. Osteoporosis is also common in patients receiving corticosteroids. </p>         </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take livogiva"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take livogiva"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Do not use Livogiva 
* if you are allergic to teriparatide or any of the other ingredients of this medicine (listed in 
section 6). 
* if you suffer from high calcium levels (pre-existing hypercalcaemia). 
* if you suffer from serious kidney problems.<br />
<em> if you have ever been diagnosed with bone cancer or other cancers that have spread 
(metastasised) to your bones.<br />
</em> if you have certain bone diseases. If you have a bone disease, tell your doctor.<br />
<em> if you have unexplained high levels of alkaline phosphatase in your blood, which means you 
might have Paget s disease of bone (disease with abnormal bone changes). If you are not sure, 
ask your doctor.<br />
</em> if you have had radiation therapy involving your bones.<br />
* if you are pregnant or breast-feeding.  </p>
<p>Warnings and precautions<br />
Livogiva may cause an increase in the amount of calcium in your blood or urine. 
Talk to your doctor or pharmacist before or while using Livogiva:<br />
<em> if you have continuing nausea, vomiting, constipation, low energy, or muscle weakness. These 
may be signs there is too much calcium in your blood.<br />
</em> if you suffer from kidney stones or have a history of kidney stones.<br />
* if you suffer from kidney problems (moderate renal impairment).  </p>
<p>Some patients get dizzy or get a fast heartbeat after the first few doses. For the first doses, inject 
Livogiva where you can sit or lie down right away if you get dizzy.<br />
The recommended treatment time of 24 months should not be exceeded.  </p>
<p>Livogiva should not be used in growing adults. </p>
<p>Children and adolescents 
Livogiva should not be used in children and adolescents (less than 18 years). </p>
<p>Other medicines and Livogiva 
Tell your doctor or pharmacist if you are taking, have recently taken or might take any other 
medicines, because occasionally they may interact (e.g. digoxin/digitalis, a medicine used to treat heart 
disease). </p>
<p>Pregnancy and breast-feeding 
Do not use Livogiva if you are pregnant or breast-feeding. If you are a woman of child-bearing 
potential, you should use effective methods of contraception during use of Livogiva. If you become 
pregnant, Livogiva should be discontinued. Ask your doctor or pharmacist for advice before taking 
any medicine.  </p>
<p>Driving and using machines 
Some patients may feel dizzy after injecting Livogiva. If you feel dizzy you should not drive or use 
machines until you feel better </p>
<p>Livogiva contains sodium 
This medicine contains less than 1 mmol sodium (23 mg) per dose, that is to say essentially  sodium-
free . </p>         </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take livogiva"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take livogiva"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Always use this medicine exactly as your doctor has told you to. Check with your doctor or pharmacist 
if you are not sure.  </p>
<p>The recommended dose is 20 micrograms given once daily by injection under the skin (subcutaneous 
injection) in the thigh or abdomen. To help you remember to use your medicine, inject it at about the 
same time each day.  </p>
<p>Inject Livogiva each day for as long as your doctor prescribes it for you. The total duration of 
treatment with Livogiva should not exceed 24 months. You should not receive more than one 
treatment course of 24 months over your lifetime.  </p>
<p>Your doctor may advise you to use Livogiva with calcium and vitamin D. Your doctor will tell you 
how much you should take each day. </p>
<p>Read the user manual, which is included in the carton for instructions on how to use the Livogiva pen.  </p>
<p>Injection needles are not included with the pen. Pen needles 29 to 31 gauge (diameter 0.25-0.33 mm) 
can be used. 
You should use your Livogiva injection shortly after you take the pen out of the refrigerator as 
described in the user manual. Put the pen back into the refrigerator immediately after you have used it.<br />
Use a new injection needle for each injection and dispose of it after each use. Never store your pen 
with the needle attached. Never share your Livogiva pen with others.  </p>
<p>Livogiva can be given with or without food. </p>
<p>If you use more Livogiva than you should 
If, by mistake, you have used more Livogiva than you should, contact your doctor or pharmacist.  </p>
<p>The effects of overdose that might be expected include nausea, vomiting, dizziness, and headache.  </p>
<p>If you forget or cannot take Livogiva at your usual time, use it as soon as possible on that day. Do 
not use a double dose to make up for a forgotten dose. Do not use more than one injection in the same 
day. Do not try to make up for a missed dose.  </p>
<p>If you stop taking Livogiva 
If you are considering stopping Livogiva treatment, please discuss this with your doctor. Your doctor 
will advise you and decide how long you should be treated with Livogiva.  </p>
<p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist. </p>         </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Like all medicines, this medicine can cause side effects, although not everybody gets them. </p>
<p>The most common side effects are pain in limb (frequency is very common, may affect more than 1 in 
10 people) and feeling sick, headache and dizziness (frequency is common). If you become dizzy 
(light-headed) after your injection, you should sit or lie down until you feel better. If you do not feel 
better, you should call a doctor before you continue treatment. Cases of fainting have been reported in 
association with teriparatide use.<br />
If you experience discomfort such as redness of the skin, pain, swelling, itching, bruising or minor 
bleeding around the area of the injection (frequency is common), this should clear up in a few days or 
weeks. Otherwise tell your doctor as soon as possible.<br />
Some patients may have experienced allergic reactions soon after injection, consisting of 
breathlessness, swelling of the face, rash and chest pain (frequency is rare). In rare cases, serious and 
potentially life-threatening allergic reactions including anaphylaxis can occur. </p>
<p>Other side effects include:<br />
Common: may affect up to 1 in 10 people<br />
<em> increase in blood cholesterol levels<br />
</em> depression<br />
<em> neuralgic pain in the leg<br />
</em> feeling faint<br />
<em> irregular heart beats<br />
</em> breathlessness<br />
<em> increased sweating<br />
</em> muscle cramps<br />
<em> loss of energy<br />
</em> tiredness<br />
<em> chest pain<br />
</em> low blood pressure<br />
<em> heartburn (painful or burning sensation just below the breast bone)<br />
</em> being sick (vomiting)<br />
<em> a hernia of the tube that carries food to your stomach<br />
</em> low haemoglobin or red blood cell count (anaemia)  </p>
<p>Uncommon: may affect up to 1 in 100 people<br />
<em> increased heart rate<br />
</em> abnormal heart sound<br />
<em> shortness of breath<br />
</em> haemorrhoids (piles)<br />
<em> accidental loss or leakage of urine<br />
</em> increased need to pass water<br />
<em> weight increase<br />
</em> kidney stones<br />
<em> pain in the muscles and pain in the joints. Some patients have experienced severe back cramps 
or pain which lead to hospitalization.<br />
</em> increase in blood calcium level<br />
<em> increase in blood uric acid level<br />
</em> increase in an enzyme called alkaline phosphatase.  </p>
<p>Rare: may affect up to 1 in 1,000 people<br />
<em> reduced kidney function, including renal failure<br />
</em> swelling, mainly in the hands, feet and legs.  </p>
<p>Reporting of side effects 
If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects 
not listed in this leaflet. You can also report side effects directly via the national reporting system 
listed in Appendix V. By reporting side effects you can help provide more information on the safety of 
this medicine. </p>         </div>"""      
        
* section[=].section[+]
  * title = "5. How to store livogiva"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store livogiva"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Keep this medicine out of the sight and reach of children. </p>
<p>Do not use this medicine after the expiry date which is stated on the carton and pen after EXP. The 
expiry date refers to the last day of that month.  </p>
<p>Livogiva should be stored in a refrigerator (2 C to 8 C) at all times. You can use Livogiva for up to days after the first injection, as long as the pen is stored in a refrigerator (2 C to 8 C).  </p>
<p>Avoid placing the pens close to the ice compartment of the refrigerator to prevent freezing. Do not use 
Livogiva if it is, or has been, frozen.  </p>
<p>Each pen should be properly disposed of after 28 days, even if it is not completely empty.  </p>
<p>Livogiva contains a clear and colourless solution. Do not use Livogiva if solid particles appear or if 
the solution is cloudy or coloured. </p>
<p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to 
throw away medicines you no longer use. These measures will help to protect the environment. </p>         </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What Livogiva contains<br />
- The active substance is teriparatide. Each milliliter of the solution for injection contains 
250 micrograms of teriparatide. Each pre-filled pen of 2.7 mL contains 675 micrograms of 
teriparatide (corresponding to 250 micrograms per mL). 
- The other ingredients are glacial acetic acid, sodium acetate trihydrate, mannitol, metacresol, 
and water for injections. See section 2. What Livogiva looks like and contents of the pack 
Livogiva is a colourless and clear solution. It is supplied in a cartridge contained in a pre-filled 
disposable pen. Each pen contains 2.7 mL of solution enough for 28 doses. Livogiva is available in 
packs containing one or three pre-filled pens.  </p>
<p>Not all pack sizes may be available. </p>
<p>Marketing Authorisation Holder<br />
Theramex Ireland Limited<br />
3rd Floor Kilmore House, Park Lane, Spencer Dock<br />
DO1 YE64 Dublin 1<br />
Ireland  </p>
<p>Manufacturer 
Eurofins PROXY Laboratories (PRX) 
Archimedesweg 25 2333 CM Leiden 
Netherlands </p>
<p>This leaflet was last revised in  </p>
<p>Other sources of information 
Detailed information on this medicine is available on the European Medicines Agency web site: </p>         </div>"""      





Instance: mpdfc0d1e53a0834f3389ed5dd9c5233d8
InstanceOf: MedicinalProductDefinitionUvEpi
Title: "Medicinal Product Livogiva 20 micrograms/80 microliters solution for injection in pre-filled pen"
Description: "Livogiva 20 micrograms/80 microliters solution for injection in pre-filled pen"
Usage: #inline

 
* identifier[+].system = "http://ema.europa.eu/identifier"
* identifier[=].value = "EU/1/20/1462/001-002"
* type = http://hl7.org/fhir/medicinal-product-type#MedicinalProduct "Medicinal Product"

* domain = http://hl7.org/fhir/medicinal-product-domain#Human "Human use"

* status = http://hl7.org/fhir/publication-status#active "active"


* indication = "Livogiva is indicated in adults."


* legalStatusOfSupply = $spor-rms#100000072084 "Medicinal product subject to medical prescription"


* name
  * productName = "Livogiva 20 micrograms/80 microliters solution for injection in pre-filled pen"
  * type = $spor-productNamePartType-cs#220000000001 "Full name" 
  
  * part[0]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000002 "Invented name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000003 "Scientific name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000004 "Strength part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000005 "Pharmaceutical dose form part"
  
  * usage
    * country = urn:iso:std:iso:3166#DK "DK"
    * jurisdiction = urn:iso:std:iso:3166#DK "DK"
    * language = urn:ietf:bcp:47#en  "en"





                      
Instance: bundlepackageleaflet-en-c94b2bb5a2491f8b60f6777b6703f8a1
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for livogiva Package Leaflet for language en"
Description: "ePI document Bundle for livogiva Package Leaflet for language en"
Usage: #example




* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "EU/1/20/1462/001-002"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #en

// Composition
* entry[0].fullUrl = "Composition/composition-en-c94b2bb5a2491f8b60f6777b6703f8a1"
* entry[0].resource = composition-en-c94b2bb5a2491f8b60f6777b6703f8a1

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mpdfc0d1e53a0834f3389ed5dd9c5233d8"
* entry[=].resource = mpdfc0d1e53a0834f3389ed5dd9c5233d8
                            
                      